Skip to main content
Top
Published in: Rheumatology International 5/2010

01-03-2010 | Original Article

Prevalence of positive ppd in a cohort of rheumatoid arthritis patients

Authors: Maria Natalia Tamborenea, Guillermo Tate, Eduardo Mysler, Jose Debonis, Adrian Schijedman

Published in: Rheumatology International | Issue 5/2010

Login to get access

Abstract

The main objective of this study is to determine the prevalence of positive and anergic tuberculin skin test (ppd) in a rheumatoid arthritis cohort of patients (RA) and assess the association among ppd results and clinical and treatment variables. Patients with RA diagnosis were included. The ppd was done by Mantoux method. Positive result was considered when indurations were equal or greater than 5 mm. Anergic reaction was defined when the indurations was 0 mm. We included 105 patients (N = 105). The prevalence of positive ppd was 12.4% (n = 13), while the 87.6% (n = 92) presented a negative result. The 69.5% (n = 73) of the population were anergic to ppd. Patients with negative result received higher steroids dosages than patients with positive ppd (p < 0.04). In the multivariable model, the steroids dosage was a significant and independent predictor of negative ppd (p = 0.021, OR 0.72, 95% CI 0.55–0.95). Anergic and non-anergic patients were separated in groups, and a new analysis was done. The higher dosage of methotrexate was associated to tuberculine anergy (p = 0.025). In the multivariable model, the methotrexate dosage was a significant and independent predictor of tuberculine anergy (p = 0.005, OR 1.14, 95% CIs 1.04–1.24). In conclusion, in our cohort, the prevalence of positive ppd was lower than others studies. Among analyzed variables, the high steroid dose was a significant and independent predictor of negative ppd. The methotrexate treatment and dose were associated with ppd anergy.
Literature
1.
go back to reference Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al (2003) Adalimumab, a fully human anti tumor necrosis factor alpha monoclonal antibody, and concomitant estándar antirheumatic therapy for treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Artritis). J Rheumatol 30:2563–2571PubMed Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al (2003) Adalimumab, a fully human anti tumor necrosis factor alpha monoclonal antibody, and concomitant estándar antirheumatic therapy for treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Artritis). J Rheumatol 30:2563–2571PubMed
2.
go back to reference Klareskog L, Van Der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each alone in patients with rheumatoid arthritis: double blinded randomised controlled trial. Lancet 343:1594–1602 Klareskog L, Van Der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each alone in patients with rheumatoid arthritis: double blinded randomised controlled trial. Lancet 343:1594–1602
3.
go back to reference Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedvelved FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 342:763–769. doi:10.1056/NEJM200003163421103 CrossRef Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedvelved FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 342:763–769. doi:10.​1056/​NEJM200003163421​103 CrossRef
4.
go back to reference Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R et al (2006) The Premier Study: a multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37. doi:10.1002/art.21519 CrossRefPubMed Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R et al (2006) The Premier Study: a multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37. doi:10.​1002/​art.​21519 CrossRefPubMed
5.
go back to reference Genovese MC, Bothon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two years radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450. doi:10.1002/art.10308 CrossRefPubMed Genovese MC, Bothon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two years radiographic and clinical outcomes. Arthritis Rheum 46:1443–1450. doi:10.​1002/​art.​10308 CrossRefPubMed
6.
go back to reference Joseph K, Gershon S, Wise PR, Mirabile E et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345:1098–1104. doi:10.1056/NEJMoa011110 CrossRef Joseph K, Gershon S, Wise PR, Mirabile E et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345:1098–1104. doi:10.​1056/​NEJMoa011110 CrossRef
8.
go back to reference Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7):1986–1992. doi:10.1002/art.21137 CrossRefPubMed Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52(7):1986–1992. doi:10.​1002/​art.​21137 CrossRefPubMed
10.
go back to reference Hamdi H, Marieta X, Godoy V et al (2006) Inhibition of antituberculosis T Lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114CrossRefPubMed Hamdi H, Marieta X, Godoy V et al (2006) Inhibition of antituberculosis T Lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114CrossRefPubMed
11.
go back to reference Obrador A, San Roman LA, Muñoz P, Gassull MA et al (2003) Guia de Consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol 26(1):29–33. doi:10.1157/13042212 CrossRefPubMed Obrador A, San Roman LA, Muñoz P, Gassull MA et al (2003) Guia de Consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol 26(1):29–33. doi:10.​1157/​13042212 CrossRefPubMed
12.
13.
14.
go back to reference Corrigall VM, Garyfallos A, Panayi GS (1999) The relative proportions of secreted interleukin-2 and interleukin-10 determine the magnitude of rheumatoid arthritis T cell proliferation to the recall antigen tuberculin purified protein derivative. Rheumatol 38:1203–1207. doi:10.1093/rheumatology/38.12.1203 CrossRef Corrigall VM, Garyfallos A, Panayi GS (1999) The relative proportions of secreted interleukin-2 and interleukin-10 determine the magnitude of rheumatoid arthritis T cell proliferation to the recall antigen tuberculin purified protein derivative. Rheumatol 38:1203–1207. doi:10.​1093/​rheumatology/​38.​12.​1203 CrossRef
15.
go back to reference Loza E, Alen J, Canto F, Alarcon G (2005) Artritis Reumatoide. In: Ramos Casal M, Carrasco M, Salazar J (eds) Enfermedades Autoinmunes sistémicas y reumatológicas. Masson, Barcelona, pp 369–399 Loza E, Alen J, Canto F, Alarcon G (2005) Artritis Reumatoide. In: Ramos Casal M, Carrasco M, Salazar J (eds) Enfermedades Autoinmunes sistémicas y reumatológicas. Masson, Barcelona, pp 369–399
16.
go back to reference Fraser P (1999) Micobacterias. In: Fraser RS, Muller NL, Colman N, Pare PD (eds) Diagnóstico de las Enfermedades del tórax, Ed 4º. WD Sounders, Philadelphia, pp 790–866 Fraser P (1999) Micobacterias. In: Fraser RS, Muller NL, Colman N, Pare PD (eds) Diagnóstico de las Enfermedades del tórax, Ed 4º. WD Sounders, Philadelphia, pp 790–866
17.
go back to reference Gil Germán, Neira O, Marcone P, Sabagh E (2006) Tuberculine reactivity in chilean RA patients (abstract). J Clin Rheumatol 12(Suppl 4):S8 Gil Germán, Neira O, Marcone P, Sabagh E (2006) Tuberculine reactivity in chilean RA patients (abstract). J Clin Rheumatol 12(Suppl 4):S8
18.
go back to reference Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360–1361. doi:10.1136/ard.2004.029041 CrossRefPubMed Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360–1361. doi:10.​1136/​ard.​2004.​029041 CrossRefPubMed
19.
go back to reference Matulis G, Juni P, Villiger PM et al (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of mycobacterium tuberculosis antigen-specific interferon assay. Ann Rheum Dis 67(1):84–90CrossRefPubMed Matulis G, Juni P, Villiger PM et al (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of mycobacterium tuberculosis antigen-specific interferon assay. Ann Rheum Dis 67(1):84–90CrossRefPubMed
20.
go back to reference Small PM, Fujiwara PI (2001) Management of tuberculosis in the United States. N Engl J Med 345(3):189–200CrossRefPubMed Small PM, Fujiwara PI (2001) Management of tuberculosis in the United States. N Engl J Med 345(3):189–200CrossRefPubMed
Metadata
Title
Prevalence of positive ppd in a cohort of rheumatoid arthritis patients
Authors
Maria Natalia Tamborenea
Guillermo Tate
Eduardo Mysler
Jose Debonis
Adrian Schijedman
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1027-z

Other articles of this Issue 5/2010

Rheumatology International 5/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.